KR102533033B1 - 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 - Google Patents

다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 Download PDF

Info

Publication number
KR102533033B1
KR102533033B1 KR1020177010510A KR20177010510A KR102533033B1 KR 102533033 B1 KR102533033 B1 KR 102533033B1 KR 1020177010510 A KR1020177010510 A KR 1020177010510A KR 20177010510 A KR20177010510 A KR 20177010510A KR 102533033 B1 KR102533033 B1 KR 102533033B1
Authority
KR
South Korea
Prior art keywords
compound
treatment
pharmaceutical composition
day
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010510A
Other languages
English (en)
Korean (ko)
Other versions
KR20170052691A (ko
Inventor
데이빗 리버그
앤덜스 올슨
드미트리 가브릴로비치
율리야 네페도바
Original Assignee
액티브 바이오테크 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액티브 바이오테크 에이비 filed Critical 액티브 바이오테크 에이비
Publication of KR20170052691A publication Critical patent/KR20170052691A/ko
Application granted granted Critical
Publication of KR102533033B1 publication Critical patent/KR102533033B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020177010510A 2014-09-23 2015-09-18 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 Active KR102533033B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185892 2014-09-23
EP14185892.8 2014-09-23
PCT/EP2015/071391 WO2016042112A1 (en) 2014-09-23 2015-09-18 Quinoline carboxamides for use in the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
KR20170052691A KR20170052691A (ko) 2017-05-12
KR102533033B1 true KR102533033B1 (ko) 2023-05-15

Family

ID=51660309

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010510A Active KR102533033B1 (ko) 2014-09-23 2015-09-18 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드

Country Status (15)

Country Link
US (2) US9956212B2 (https=)
EP (1) EP3041472B1 (https=)
JP (1) JP6647287B2 (https=)
KR (1) KR102533033B1 (https=)
CN (1) CN107108510B (https=)
AU (1) AU2015316824B2 (https=)
CA (1) CA2961978C (https=)
EA (1) EA030948B1 (https=)
ES (1) ES2631194T3 (https=)
IL (1) IL251043B (https=)
MX (1) MX366837B (https=)
NZ (1) NZ730816A (https=)
PL (1) PL3041472T3 (https=)
WO (1) WO2016042112A1 (https=)
ZA (1) ZA201702377B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
AU2021229611A1 (en) * 2020-03-03 2022-10-27 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
ES3057099T3 (en) * 2021-01-18 2026-02-26 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
AU2022303084A1 (en) 2021-07-02 2024-01-25 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030758A1 (en) 1999-10-25 2001-05-03 Active Biotech Ab Drugs for the treatment of malignant tumours
WO2012066478A1 (fr) 2010-11-16 2012-05-24 Centre National De La Recherche Scientifique Dérivés de quinolinone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
CA2808417A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012034543A1 (es) 2010-09-13 2012-03-22 Universidad De Costa Rica Conector estructural para bambú
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030758A1 (en) 1999-10-25 2001-05-03 Active Biotech Ab Drugs for the treatment of malignant tumours
WO2012066478A1 (fr) 2010-11-16 2012-05-24 Centre National De La Recherche Scientifique Dérivés de quinolinone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jennbacken Karin 외, THE PROSTATE, vol.72 , no.8, 2012, 913-924쪽
Shen Li 외, CANCER RESEARCH, vol.73 , no.8, Suppl. 1, 2013, 4746쪽

Also Published As

Publication number Publication date
CN107108510A (zh) 2017-08-29
WO2016042112A1 (en) 2016-03-24
US20170273967A1 (en) 2017-09-28
EP3041472A1 (en) 2016-07-13
JP2017528473A (ja) 2017-09-28
AU2015316824A1 (en) 2017-04-27
PL3041472T3 (pl) 2017-08-31
US20180228794A1 (en) 2018-08-16
BR112017004947A2 (pt) 2017-12-05
MX2017003294A (es) 2017-06-23
IL251043B (en) 2020-02-27
IL251043A0 (en) 2017-04-30
AU2015316824B2 (en) 2020-10-29
US9956212B2 (en) 2018-05-01
EA030948B1 (ru) 2018-10-31
EP3041472B1 (en) 2017-02-01
EA201790687A1 (ru) 2017-08-31
CN107108510B (zh) 2020-10-23
US10314836B2 (en) 2019-06-11
NZ730816A (en) 2022-01-28
KR20170052691A (ko) 2017-05-12
JP6647287B2 (ja) 2020-02-14
CA2961978C (en) 2023-03-14
MX366837B (es) 2019-07-26
ES2631194T3 (es) 2017-08-29
ZA201702377B (en) 2018-08-29
CA2961978A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
KR102533033B1 (ko) 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
CN105007920B (zh) 雄激素受体调节剂及其用途
EP3180005B1 (en) Quinoline carboxamides for use in the treatment of leukemia
CN105007981B (zh) 在移植患者中治疗移植物抗宿主病
CN112368024A (zh) 治疗癌症的方法
JP2017534652A5 (https=)
AU2019398198B2 (en) CXCR7 inhibitors for the treatment of cancer
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
JP2017527627A (ja) 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ
HK1226643B (en) Quinoline carboxamides for use in the treatment of multiple myeloma
HK1226643A1 (en) Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017004947B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável
HK1237658B (en) Quinoline carboxamides for use in the treatment of leukemia
HK1237658A1 (en) Quinoline carboxamides for use in the treatment of leukemia
HK40047004A (en) Methods of treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4